1- Innovación
|
 G Bottazzi , G. Dosia, M. Lippi, F. Pammolli and M. Riccaboni
Innovation and corporate growth in the evolution of the
drug industry |
 |
Office of Health Economics
Las múltiples facetas de la innovación |
|
Jeffrey L. Furman, Michael E. Porter and Scott Stern
The determinants of national innovative capacity |
|
H. G. Grabowski and Y.R. Wang
The Quantity And Quality Of Worldwide New
Drug Introductions, 1982–2003 |
|
2- Regulación de precios
|
Cheri Grace
Equitable Pricing Of Newer Essential
Medicines For Developing Countries:
Evidence For The Potential Of Different
Mechanisms |
|
David Reiffen and Michael Ward
Generic Drug Industry Dynamics |
|
Greg Hopkins
Does The Regulation Of Pharmaceutical Drug Prices Discourage Innovation? |
|
Robert B. Helms
The Economics of Price Regulation and Innovation |
|
Vicente Ortun
Patentes, regulación de precios e innovación
en la industria farmacéutica |
|
Nicola Lacetera and Luigi Orsenigo
Political regimes, technological regimes and innovation in the
evolution of the pharmaceutical industry in the USA and in
Europe. |
|
3- Política
|
Steven Morgan, Ken Bassett and Barbara Mintzes
Outcomes-Based Drug Coverage in British
Columbia |
|
A. Anell and U. Persson
Reimbursement and clinical guidance for pharmaceuticals in Sweden |
|
Antonio Cabrales
Pharmaceutical Generics, Vertical Product
Diferentiation and Public Policy |
|
European Observatory of Health Care System Series
Regulating pharmaceuticals in europe: striving for efficiency, equity and quality. |
|
Donald WrightF
The drug bargaining game: pharmaceutical
regulation in Australia |
|
4- Competitividad
|
Alfonso Gambardella, Luigi Orsenigo and Fabio Pammolli
Global Competitiveness in Pharmaceuticals a European Perspective |
|
G10-Medicines
High Level Group
on innovation
and provision
of medicines |
|
5- Financiación
|
Aidan Hollis
An Efficient Reward System for Pharmaceutical Innovation |
|
6- Miscelánea
|
JSB Intelligence
Strategic Analysis of the Pharma Market, Future
Revenue Models and Key Players |
|
Tomas Philipson and Caroline Dai
Between- vs.Within-Patent
Competition |
|
L. Orsenigo, F. Pammolli and Massimo Riccaboni
Technological change and network dynamics. Lessons from the pharmaceutical industry
Lessons from the pharmaceutical industry |
|
Donald W Light and Joel Lexchin
Foreign free riders and the high price of US medicines |
|
David Reiffen
“Branded Generics” As A Strategy To Limit
Cannibalization Of Pharmaceutical Markets |
|
7- Otros
|
Comisión Interministerial de Ciencia y Tecnología
Programa Ingenio 2010 |
|
EPFIA
Innovative Medicines for Europe. Creating biomedical R&D leadership for Europe to benefit patients and society |
|
Eurobarómetro
Special EUROBAROMETER 224 “Europeans, Science & Technology”. June 2005 |
|
Corinne Autant-Bernard
Where do firms choose to locate their R&D?
A spatial conditional logit analysis on French data. |
|
Internal Co-ordination Group for Health (ICGH)
OECD Health Update No. 2 – January 2006 |
|
J.Owen-Smith, M. Riccaboni, F. Pammolli, W. Powell
A Comparison of U.S. and European University-Industry Relations in the Life Sciences |
|
Gobierno Español
Anteproyecto de Ley de Garantías y Uso Racional de los Medicamentos
y Productos Sanitarios |
|
